Photodynamic therapy for early oesophageal cancer.
BACKGROUND
Photodynamic therapy is an endoscopic treatment of early cancers based on the photosensitisation of neoplasms following the administration of a photosensitiser prior to laser light-induced tissue destruction.


OBJECTIVE
To assess the results of photodynamic therapy using Photofrin(Axcan Pharma Inc., Quebec, Canada) in patients with an early oesophageal cancer.


METHODS
Twenty-four patients with early oesophageal cancer presenting as a not well-demarcated irregular dyschromic area of mucosa and unsuitable for any other treatment underwent photodynamic therapy. RESULTS.: Seventy-five per cent were successfully treated; three of them recurred and two died from head and neck cancer. To date, 54% of patients are alive without recurrence; the average follow-up is 21 months. There were one oesophageal lethal perforation and six stenosis. Results of photodynamic therapy were limited in this series by three failures, three recurrences and three deaths from previous head and neck cancers.


CONCLUSIONS
This study provides some promising data for photodynamic therapy of oesophageal carcinomas in selected patients. It also emphasises the need for a best delivery device of laser light.
Gastroenterology Department, University Hospital, Lille, France. vmaunoury@chru-lille.fr
V
V
Maunoury
S
S
Mordon
P
P
Bulois
X
X
Mirabel
B
B
Hecquet
C
C
Mariette
D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D017323:Dihematoporphyrin Ether / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D004945:Esophagoscopy; D005260:Female; D006414:Hematoporphyrin Photoradiation; D006801:Humans; D008297:Male; D008875:Middle Aged
D017323:Dihematoporphyrin Ether